{
  "ticker": "NEU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962277",
  "id": "02962277",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250626",
  "time": "0925",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250626/pdf/06l40y997bqx7l.pdf",
  "summary": "- **US patent allowed** for NNZ-2591 to treat Pitt Hopkins syndrome (PTHS), with **expiry in April 2040**.  \n- **Orphan Drug and Fast Track designations** granted by FDA for NNZ-2591 in PTHS.  \n- **Phase 2 trial results**: 9/11 children showed clinician-assessed improvement; 8/11 caregiver-assessed improvement.  \n- **Phase 3 trial planned** for NNZ-2591 in Phelan-McDermid syndrome.",
  "usage": {
    "prompt_tokens": 1079,
    "completion_tokens": 114,
    "total_tokens": 1193,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-25T23:35:30.201917"
}